Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 28, 2022; 28(40): 5818-5826
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5818
Table 1 Interrim results of selective drug trials for non-alcoholic fatty liver disease and liver fibrosis
Phase number
SimtuzumabLysyl oxidase-like 2 monoclonal antibodyIIbNCT01672879Ineffective in decreasing hepatic venous pressure gradient
SelonsertibSelective inhibitor of apoptosis signal-regulating kinase 1IIINCT03053063Ineffective in improving fibrosis without worsening NASH
EmricasanPan-caspase inhibitorIINCT03205345No reduction in composite outcome of mortality and decompensation
PegbelferminPEGylated fibroblast growth factor 21 analogueIIaNCT03486912Ineffective in improving fibrosis without worsening NASH
LanifibranorPan peroxisome proliferator-activated receptor agonistsIIINCT04849728Decrease of ≥ 2 points in the Steatosis Activity Fibrosis score without worsening of fibrosis in phase 2b trial
ResmetiromThyroid hormone receptor agonistIIINCT03900429Significant reductions in liver fat content and serum atherogenic lipids in phase 2 trial
AramcholHepatic stearoyl-CoA desaturase1 inhibitorIIbNCT02279524Insignificant decrease in liver triglycerides but significant improvement in liver inflammation and improvement of fibrosis ≥ 1 stage and serum ALT level
LeronlimabChemokine receptor 5 monoclonal antibodyIINCT04521114Significant drops in liver fat, inflammation and fibrosis values as also in liver enzymes and multiple inflammation markers at week 14 compared to placebo